↓ Skip to main content

EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy

Overview of attention for article published in Clinical and Translational Allergy, October 2012
Altmetric Badge

About this Attention Score

  • In the top 25% of all research outputs scored by Altmetric
  • Among the highest-scoring outputs from this source (#39 of 756)
  • High Attention Score compared to outputs of the same age (95th percentile)
  • Good Attention Score compared to outputs of the same age and source (71st percentile)

Mentioned by

3 blogs
15 X users
1 patent
1 Facebook page


98 Dimensions

Readers on

167 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
EAACI: A European Declaration on Immunotherapy. Designing the future of allergen specific immunotherapy
Published in
Clinical and Translational Allergy, October 2012
DOI 10.1186/2045-7022-2-20
Pubmed ID

Moises A Calderon, Pascal Demoly, Roy Gerth van Wijk, Jean Bousquet, Aziz Sheikh, Anthony Frew, Glenis Scadding, Claus Bachert, Hans J Malling, Rudolph Valenta, Beatrice Bilo, Antonio Nieto, Cezmi Akdis, Jocelyne Just, Carmen Vidal, Eva M Varga, Emilio Alvarez-Cuesta, Barbara Bohle, Albrecht Bufe, Walter G Canonica, Victoria Cardona, Ronald Dahl, Alain Didier, Stephen R Durham, Peter Eng, Montserrat Fernandez-Rivas, Lars Jacobsen, Marek Jutel, Jörg Kleine-Tebbe, Ludger Klimek, Jan Lötvall, Carmen Moreno, Ralph Mosges, Antonella Muraro, Bodo Niggemann, Giovanni Pajno, Giovanni Passalacqua, Oliver Pfaar, Sabina Rak, Gianenrico Senna, Gabriela Senti, Erkka Valovirta, Marianne van Hage, Johannes C Virchow, Ulrich Wahn, Nikolaos Papadopoulos


Allergy today is a public health concern of pandemic proportions, affecting more than 150 million people in Europe alone. In view of epidemiological trends, the European Academy of Allergy and Clinical Immunology (EAACI) predicts that within the next few decades, more than half of the European population may at some point in their lives experience some type of allergy.Not only do allergic patients suffer from a debilitating disease, with the potential for major impact on their quality of life, career progression, personal development and lifestyle choices, but they also constitute a significant burden on health economics and macroeconomics due to the days of lost productivity and underperformance. Given that allergy triggers, including urbanization, industrialization, pollution and climate change, are not expected to change in the foreseeable future, it is imperative that steps are taken to develop, strengthen and optimize preventive and treatment strategies.Allergen specific immunotherapy is the only currently available medical intervention that has the potential to affect the natural course of the disease. Years of basic science research, clinical trials, and systematic reviews and meta-analyses have convincingly shown that allergen specific immunotherapy can achieve substantial results for patients, improving the allergic individuals' quality of life, reducing the long-term costs and burden of allergies, and changing the course of the disease. Allergen specific immunotherapy not only effectively alleviates allergy symptoms, but it has a long-term effect after conclusion of the treatment and can prevent the progression of allergic diseases.Unfortunately, allergen specific immunotherapy has not yet received adequate attention from European institutions, including research funding bodies, even though this could be a most rewarding field in terms of return on investments, translational value and European integration and, a field in which Europe is recognized as a worldwide leader. Evaluation and surveillance of the full cost of allergic diseases is still lacking and further progress is being stifled by the variety of health systems across Europe. This means that the general population remains unaware of the potential use of allergen specific immunotherapy and its potential benefits.We call upon Europe's policy-makers to coordinate actions and improve individual and public health in allergy by:Promoting awareness of the effectiveness of allergen specific immunotherapyUpdating national healthcare policies to support allergen specific immunotherapyPrioritising funding for allergen specific immunotherapy researchMonitoring the macroeconomic and health economic parameters of allergyReinforcing allergy teaching in medical disciplines and specialtiesThe effective implementation of the above policies has the potential for a major positive impact on European health and well-being in the next decade.

X Demographics

X Demographics

The data shown below were collected from the profiles of 15 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 167 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Spain 1 <1%
Netherlands 1 <1%
Germany 1 <1%
Unknown 164 98%

Demographic breakdown

Readers by professional status Count As %
Researcher 29 17%
Student > Ph. D. Student 19 11%
Other 17 10%
Student > Master 16 10%
Student > Bachelor 12 7%
Other 35 21%
Unknown 39 23%
Readers by discipline Count As %
Medicine and Dentistry 52 31%
Agricultural and Biological Sciences 14 8%
Immunology and Microbiology 10 6%
Biochemistry, Genetics and Molecular Biology 9 5%
Social Sciences 7 4%
Other 27 16%
Unknown 48 29%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 29. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 December 2019.
All research outputs
of 25,374,917 outputs
Outputs from Clinical and Translational Allergy
of 756 outputs
Outputs of similar age
of 202,137 outputs
Outputs of similar age from Clinical and Translational Allergy
of 7 outputs
Altmetric has tracked 25,374,917 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 94th percentile: it's in the top 10% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 756 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 10.7. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,137 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 95% of its contemporaries.
We're also able to compare this research output to 7 others from the same source and published within six weeks on either side of this one. This one has scored higher than 5 of them.